BrightSpring Health Services, Inc. (BTSG) FY2025 10-K Annual Report
BrightSpring Health Services, Inc. (BTSG) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 27, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
BrightSpring Health Services, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Integrated home and community-based healthcare platform delivering complementary pharmacy and provider services to complex Senior and Specialty patients
- • Strategic shift: Divestiture of Community Living business for $835M, focusing on streamlined Provider Services like home health, hospice, rehab, and primary care
- • New emphasis: Expanded home-based primary care and value-based care contracts leveraging integrated pharmacy-provider model to improve outcomes and reduce costs
- • Scale and reach: Serving over 465,000 patients daily via ~10,500 clinical providers and pharmacists across all 50 states, with 43M prescriptions filled in 2025
- • Noteworthy metric: Infusion and specialty pharmacy prescriptions grew 27%, home and community pharmacy 3% from 2024 to 2025, with 99.99% order accuracy and 99.34% completeness
Management Discussion & Analysis
- • Consolidated revenue $12.91B in 2025, up 27.7% YoY from $10.12B in 2024; Pharmacy Solutions best performing segment, up 30.7% to $11.45B; Provider Services up 11.1% to $1.46B
- • Operating margin Pharmacy Solutions 3.8% vs 3.2%; Provider Services operating margin 14.0% vs 13.7%; consolidated EBITDA $776.2M, up 33.7% from $580.0M
- • Pharmacy Solutions segment EBITDA $543.5M, up 37.7%; Provider Services segment EBITDA $232.7M, up 13.3%; Pharmacy Solutions margin lower due to product mix shift
- • Net cash provided by operating activities $490.2M vs $23.8M; investing cash used $305.1M vs $140.2M (includes $144.8M acquisition spend); financing cash used $157.9M primarily debt repayment and $43.2M share repurchases
- • Management expects existing liquidity including $565.6M cash and revolving credit availability sufficient for next 12 months; key risks include integration costs, specialty drug mix shift affecting margins
Risk Factors
- • Medicare Home Health Prospective Payment System changes, including PDGM implemented 2020, affecting reimbursement based on patient mix and admission source
- • Exposure to Medicaid Integrity Program audits in six states, causing administrative costs and payment delays through 2029 under Review Choice Demonstration
- • Supplier relationship risk in Pharmacy Solutions, including loss of access to limited distribution pharmaceuticals impacting competitive positioning
- • Competition from vertically integrated rivals with exclusive pharmaceutical supply contracts and retail pharmacy chains limiting price competitiveness
- • Managed care contract risk with payors able to terminate contracts on 60-day notice, creating leverage to reduce volume or pricing favorable to payors
BrightSpring Health Services, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$12.9B
▲ +14.6% YoY
Net Income
$191M
▲ +1155.6% YoY
Gross Margin
11.8%
▼ -234bp YoY
Operating Margin
2.3%
▲ +46bp YoY
Net Margin
1.5%
▲ +164bp YoY
ROE
10.2%
▲ +1126bp YoY
Total Assets
$6.4B
▲ +8.2% YoY
EPS (Diluted)
$0.87
▲ +1066.7% YoY
Operating Cash Flow
$490M
▲ +1961.8% YoY
Source: XBRL data from BrightSpring Health Services, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on BrightSpring Health Services, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.